The neuropeptide FF (NPFF) system has been implicated in a number of physiological processes including modulating the pharmacological activity of opioid analgesics and several other classes of drugs of abuse. In this study, we report the discovery of a novel proline scaffold with antagonistic activity at the NPFF receptors through a high throughput screening campaign using a functional calcium mobilization assay. Focused structure-activity relationship studies on the initial hit 1 have resulted in several analogs with calcium mobilization potencies in the submicromolar range and modest selectivity for the NPFF1 receptor. Affinities and potencies of these compounds were confirmed in radioligand binding and functional cAMP assays. Two compounds, 16 and 33, had good solubility and blood-brain barrier permeability that fall within the range of CNS permeant candidates without the liability of being a P-glycoprotein substrate. Finally, both compounds reversed fentanyl-induced hyperalgesia in rats when administered intraperitoneally. Together, these results point to the potential of these proline analogs as promising NPFF receptor antagonists.
Discovery of novel proline-based neuropeptide FF receptor antagonists
Nguyen, T., Decker, A. M., Langston, T. L., Mathews, K. M., Siemian, J. N., Li, J-X., Harris, D. L., Runyon, S. P., & Zhang, Y. (2017). Discovery of novel proline-based neuropeptide FF receptor antagonists. ACS Chemical Neuroscience, 8(10), 2290-2308. https://doi.org/10.1021/acschemneuro.7b00219